Tuğçe Tural KARA, Halil ÖZDEMİR, Tuğba ERAT, Aysun YAHŞİ, Ahmet Derya AYSEV, Nurdan TAÇYILDIZ, Emel ÜNAL, Talia İLERİ, Elif İNCE, Şule HASKOLOĞLU, Ergin ÇİFTÇİ, Erdal İNCE

Is antibiotic lock therapy effective for the implantable longterm catheter-related bloodstream infections in children?

Catheter-related bloodstream infections (CRBSIs) are an important problemin pediatric patients with central venous catheters. This study aimed todetermine the incidence of CRBSIs, responsible pathogens and outcomes ofantibiotic lock treatment (ALT) in pediatric patients. Between January 2010and November 2015 all hospitalized pediatric hematology, oncology andimmunology patients diagnosed with CRBSIs were retrospectively analyzed.Seventy-eight CRBSI episodes were detected in 60 pediatric patients. Theincidence of CRBSIs was 4.20/1000 catheter days. The most frequentlydetected pathogen was methicillin-resistant coagulase-negative Staphylococcus.Pseudomonas aeruginosa, Klebsiella spp., and Escherichia coli were other commonlyisolated microorganisms. ALT was administered in 42 patients. The successrate of ALT was 81% (34/42). Catheter was removed without ALT in 36episodes. Common reasons for catheter removal were sepsis and causativemicroorganisms which had high probability of biofilm formation.CRBSIs are an important cause of morbidity and mortality in pediatricpatients. ALT is safe and effective. It is possible to obtain satisfactory resultswhen ALT is used with intravenous systemic antibiotics for CRBSIs, though insome cases catheter removal is necessary. ALT helps to prevent unnecessarycatheter removal in pediatric patients.

PDF

___

1. Chesshyre E, Goff Z, Bowen A, Carapetis J. The prevention, diagnosis and management of central venous line infections in children. J Infect 2015; 71(Suppl 1): S59-S75.

2. Wolf J, Allison KJ, Tang L, Sun Y, Hayden RT, Flynn PM. No evidence of benefit from antibiotic lock therapy in pediatric oncology patients with central line-related bloodstream infection: results of a retrospective matched cohort study and review of the literature. Pediatr Blood Cancer 2014; 61: 1811-1815.

3. Adler A, Yaniv I, Solter E, et al. Catheter-associated bloodstream infections in pediatric hematologyoncology patients: factors associated with catheter removal and recurrence. J Pediatr Hematol Oncol 2006; 28: 23-28.

4. Goudie A, Dynan L, Brady PW, Rettiganti M. Attributable cost and length of stay for central lineassociated bloodstream infections. Pediatrics 2014; 133: e1525-e1532.

5. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.

6. Sievert DM, Ricks P, Edwards JR, et al; National Healthcare Safety. Network (NHSN) Team and Participating NHSN Facilities. Antimicrobialresistant pathogens associated with healthcareassociated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009- 2010. Infect Control Hosp Epidemiol 2013; 34: 1-14.

7. Flynn PM. Diagnosis and management of central venous catheter-related bloodstream infections in pediatric patients. Pediatr Infect Dis J 2009; 28: 1016- 1017.

8. Cecinati V, Brescia L, Tagliaferri L, Giordano P, Esposito S. Catheter-related infections in pediatric patients with cancer. Eur J Clin Microbiol Infect Dis 2012; 31: 2869-2877.

9. Yacobovich J, Ben-Ami T, Abdalla T, et al. Patient and central venous catheter related risk factors for blood stream infections in children receiving chemotherapy. Pediatr Blood Cancer 2015; 62: 471-476.

10. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771- 1776.

11. De Sio L, Jenkner A, Milano GM, et al. Antibiotic lock with vancomycin and urokinase can successfully treat colonized central venous catheters in pediatric cancer patients. Pediatr Infect Dis J 2004; 23: 963-965.

12. Kar YD, Özdemir ZC, Bör Ö. Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients. Turk Pediatri Ars 2017; 52: 213-220.

13. Tsai HC, Huang LM, Chang LY, et al. Central venous catheter-associated bloodstream infections in pediatric hematology-oncology patients and effectiveness of antimicrobial lock therapy. J Microbiol Immunol Infect 2015; 48: 639-646.

14. Celebi S, Sezgin ME, Cakır D, et al. Catheterassociated bloodstream infections in pediatric hematology-oncology patients. Pediatr Hematol Oncol 2013; 30: 187-194.

15. Berrueco R, Rives S, Català A, et al. Prospective surveillance study of blood stream infections associated with central venous access devices (port-type) in children with acute leukemia: an intervention program. J Pediatr Hematol Oncol 2013; 35: e194-e199.

16. Kao HF, Chen IC, Hsu C, et al. Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. Support Care Cancer 2014; 22: 1189- 1197.

17. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother 2005; 55: 90-94.

18. Carratalà J. The antibiotic-lock technique for therapy of 'highly needed' infected catheters. Clin Microbiol Infect 2002; 8: 282-289.

19. O'Horo JC, Silva GL, Safdar N. Anti-infective locks for treatment of central line-associated bloodstream infection: a systematic review and meta-analysis. Am J Nephrol 2011; 34: 415-422.

20. Mermel LA, Farr BM, Sherertz RJ, et al; Infectious Diseases Society of America; American College of Critical Care Medicine; Society for Healthcare Epidemiology of America. Guidelines for the management of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2001; 22: 222-242.

21. Del Pozo JL, Alonso M, Serrera A, Hernaez S, Aguinaga A, Leiva J. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. Diagn Microbiol Infect Dis 2009; 63: 208-212.

22. Moreno RB, Rives S, Justicia A, et al. Successful porta-cath salvage using linezolid in children with acute leukemia. Pediatr Blood Cancer 2013; 60: E103-E105.

23. Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, noncomparative study. J Antimicrob Chemother 2006; 57: 1172-1180.

24. Fortún J, Grill F, Martín-Dávila P, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic-lock therapy. J Antimicrob Chemother 2006; 58: 816-821.

25. Funalleras G, Fernández-Hidalgo N, Borrego A, et al. Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to Gram-negative bacilli: a prospective observational study. Clin Infect Dis 2011; 53: e129-e132.

26. Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenges. Infect Drug Resist 2014; 7: 343-363.

27. Yevzlin AS, Sanchez RJ, Hiatt JG, et al. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Semin Dial 2007; 20: 351-354.

28. Saxena AK, Panhotra BR, Naguib M. Sudden irreversible sensory-neural hearing loss in a patient with diabetes receiving amikacin as an antibioticheparin lock. Pharmacotherapy 2002; 22: 105-108.